ArticleVaccine2012
Research priorities for global measles and rubella control and eradication.
Article in Vaccine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 50 citations in OpenAlex.
- Collective Immunity to the Measles, Mumps, and Rubella Viruses in the Kyrgyz Population.Vaccines · 2025Article
- Modeling the Cost of Vaccinating a Measles Zero-Dose Child in Zambia Using Three Vaccination Strategies.The American journal of tropical medicine and hygiene · 2024Article
- Innovations in vaccine delivery: increasing access, coverage, and equity and lessons learnt from measles and rubella elimination.Drug delivery and translational research · 2022Article
- Thermostability of Measles and Rubella Vaccines in a Microneedle Patch.Advanced therapeutics · 2021Article
- Strategies for elimination of rubella in pregnancy and of congenital rubella syndrome in high and upper-middle income countries.Journal of preventive medicine and hygiene · 2020Review
- Global trends in measles publications.The Pan African medical journal · 2020Review
- Article
- Article
- Article
- Measles and rubella elimination: learning from polio eradication and moving forward with a diagonal approach.Expert review of vaccines · 2017Review
- Demographic transition and the dynamics of measles in six provinces in China: A modeling study.PLoS medicine · 2017Article
- Assessing the Potential Cost-Effectiveness of Microneedle Patches in Childhood Measles Vaccination Programs: The Case for Further Research and Development.Drugs in R&D · 2016Article
- Impact on Epidemic Measles of Vaccination Campaigns Triggered by Disease Outbreaks or Serosurveys: A Modeling Study.PLoS medicine · 2016Article
- Modeling and Managing the Risks of Measles and Rubella: A Global Perspective, Part I.Risk analysis : an official publication of the Society for Risk Analysis · 2016Article
- Synthesis of Evidence to Characterize National Measles and Rubella Exposure and Immunization Histories.Risk analysis : an official publication of the Society for Risk Analysis · 2016Article
- Article
- Vaccine receipt and vaccine card availability among children of the apostolic faith: analysis from the 2010-2011 Zimbabwe demographic and health survey.The Pan African medical journal · 2016Article
- Article
- An orally available, small-molecule polymerase inhibitor shows efficacy against a lethal morbillivirus infection in a large animal model.Science translational medicine · 2014Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 5 countries.
Funding
Abstract
In 2010, an expert advisory panel convened by the World Health Organization to assess the feasibility of measles eradication concluded that (1) measles can and should be eradicated, (2) eradication by 2020 is feasible if measurable progress is made toward existing 2015 measles mortality reduction targets, (3) measles eradication activities should occur in the context of strengthening routine immunization services, and (4) measles eradication activities should be used to accelerate control and elimination of rubella and congenital rubella syndrome (CRS). The expert advisory panel also emphasized the critical role of research and innovation in any disease control or eradication program. In May 2011, a meeting was held to identify and prioritize research priorities to support measles and rubella/CRS control and potential eradication activities. This summary presents the questions identified by the meeting participants and their relative priority within the following categories: (1) measles epidemiology, (2) vaccine development and alternative vaccine delivery, (3) surveillance and laboratory methods, (4) immunization strategies, (5) mathematical modeling and economic analyses, and (6) rubella/CRS control and elimination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.